Catalyst Pharmaceuticals Inc Stock Price, News & Analysis

Catalyst Pharmaceuticals (CPRX) reported strong financial results for Q4 and full year 2024, with total revenues reaching $491.7 million, marking a 23.5% year-over-year growth. The company's portfolio performance was driven by three key products: FIRDAPSE® ($306.0M), AGAMREE® ($46.0M), and FYCOMPA® ($137.3M).

Q4 2024 revenues were $141.8 million, up 28.3% YoY, with GAAP net income of $55.9 million. The company projects 2025 total revenues between $545-565 million, with FIRDAPSE expected to generate $355-360M, AGAMREE $100-110M, and FYCOMPA $90-95M.

Notable achievements include AGAMREE's successful US launch, FIRDAPSE's FDA-approved dose increase, and a settlement agreement with Teva regarding patent litigation. The company ended 2024 with $517.6 million in cash and cash equivalents.

Catalyst Pharmaceuticals (CPRX) has announced it will release its fourth quarter and full-year 2024 financial results after market close on February 26, 2025. The company will host a conference call and webcast the following day, February 27, 2025, at 8:30 AM ET, where management will discuss financial results and provide a business update.

The conference call will be accessible via US/Canada dial-in number (877) 407-8912 and international dial-in (201) 689-8059. A webcast will be available under the Investors section on the company's website, with a replay accessible for at least 30 days following the event.

Catalyst Pharmaceuticals (NASDAQ: CPRX) has achieved a remarkable fifth place ranking on Forbes' 2025 list of America's Most Successful Mid-Cap Companies. This achievement follows their fourth-place position on Forbes' Small-Cap Companies list from the previous year, demonstrating the company's successful growth trajectory.

The ranking criteria included earnings growth, sales growth, return on equity, and total stock return over a five-year period, with greater emphasis on the most recent year's performance. Forbes' selection process involved screening over 700 companies with market values between $2 billion and $10 billion, requiring positive sales growth over 12 months and a minimum share price of $5. The data was collected as of November 27, 2024.

Companies excluded from consideration included financial institutions, REITs, utilities, partnerships, and those public for less than one year. CEO Rich Daly attributed this success to their growth and investment strategy, emphasizing their commitment to patient care and stakeholder value creation.

Catalyst Pharmaceuticals (CPRX) announced that its sub-licensee DyDo Pharma has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan. The drug is approved for improving muscle weakness in patients with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder.

FIRDAPSE is the only FDA-approved therapy for LEMS treatment in adults and pediatric patients six years and older. This launch represents an expansion of Catalyst's geographic footprint and increases access to the therapy for Japanese patients. In the U.S., FIRDAPSE is supported by a comprehensive patient support program to ensure accessibility for eligible patients.

Catalyst Pharmaceuticals (CPRX) and its licensor SERB S.A. have reached a settlement agreement with Teva Pharmaceuticals regarding patent litigation over FIRDAPSE® (amifampridine). The litigation was initiated after Teva filed an Abbreviated New Drug Application seeking to market a generic version of FIRDAPSE 10 mg tablets before patent expiration.

Under the agreement, Teva will not market its generic version of FIRDAPSE in the United States before February 25, 2035, pending FDA approval. The ongoing patent litigation between Catalyst/SERB and Teva in the U.S. District Court for the District of New Jersey will be terminated. However, patent litigation continues against other defendants, including Hetero and Lupin.

Catalyst Pharmaceuticals (NASDAQ: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Richard J. Daly, will deliver a presentation on Thursday, January 16, 2025, at 10:30 am PST in San Francisco.

The presentation will be accessible via webcast through the Investors section of Catalyst's website, with a replay available for a minimum of 30 days following the event. This conference represents a significant platform for Catalyst to showcase its developments in novel medicines and treatments.

Catalyst Pharmaceuticals (NASDAQ: CPRX) has been ranked 452nd on the 2024 Deloitte Technology Fast 500™ list, showcasing North America's fastest-growing companies across technology, media, telecommunications, life sciences, fintech, and energy tech sectors. The company achieved 234% revenue growth between 2020 and 2023, attributed to operational excellence and strong commercial execution.

The 30th annual rankings featured companies with growth rates ranging from 201% to 153,625%, with an average of 1,981% and a median of 460%. Notably, this year marked a significant breakthrough in private company performance, with the software and fintech sectors showing particularly strong representation.

Catalyst Pharmaceuticals (Nasdaq: CPRX) has announced its participation in two major upcoming investor conferences. The company's President and CEO Richard J. Daly, along with other management team members, will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 2:00 PM ET, and at Citi's 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 1:00 PM ET. Both presentations will be available via webcast on the company's website under the Investors section, with replays accessible for at least 30 days.

Catalyst Pharmaceuticals (Nasdaq: CPRX) has been named among the BioSpace 2025 Best Places to Work, joining 50 other U.S. employers recognized as the most sought-after in the industry. The recognition comes from votes and ratings by thousands of life sciences community members, evaluating companies based on culture, career growth, leadership, and innovation.

The selection process, conducted in 2024, involved nominations in June and voting in August, with over 3,000 life sciences professionals rating organizations on factors including compensation, innovation, career opportunities, leadership, culture, DEI, reputation, and work flexibility. President and CEO Richard J. Daly highlighted the company's commitment to creating an environment that promotes growth, development, and trust while focusing on improving patient care for rare diseases.